ReviewAmerican journal of respiratory and critical care medicine2017
AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future.
Review in American journal of respiratory and critical care medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer.Frontiers in oncology · 2022Pooled it
- Physiologic and psychologic adaptation to exercise interventions in lung cancer patients undergoing chemotherapy: a systematic review and meta-analysis of randomized controlled trials.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Pooled it
- Trial
- Thoracic surgery in the era of targeted and/or oral therapies for hematologic malignancies: a retrospective case series of postoperative hemorrhagic complications.Journal of thoracic disease · 2026Article
- Maintaining momentum: the history and future of lung cancer disparities in the United States.Frontiers in oncology · 2026Review
- Curative intent therapy of stage I-III non-small cell lung cancer: a patient-centered precision approach to assess, measure, and interpret benefits and harms.Journal of thoracic disease · 2025Article
- Trends in Overall Survival in Lung Adenocarcinoma with EGFR Mutation, KRAS Mutation, or No Mutation.Cancers · 2025Article
- Current and Future Applications of PET Radiomics in Radiation Oncology.PET clinics · 2025Review
- Patterns of recurrence among adults diagnosed with screen-detected lung cancer.Cancer epidemiology · 2025Article
- The causal association between neutrophil counts and the risk of lung cancer: a Mendelian randomization study.Journal of Cancer · 2025Article
- Rabenosyn-5 suppresses non-small cell lung cancer metastasis via inhibiting CDC42 activity.Cancer gene therapy · 2024Article
- Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.Cancer letters · 2024Article
- Smoking status and the association between patient-level factors and survival among lung cancer patients.Journal of the National Cancer Institute · 2023Article
- Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.bioRxiv : the preprint server for biology · 2023Article
- Development of a multi-feature-combined model: proof-of-concept with application to local failure prediction of post-SBRT or surgery early-stage NSCLC patients.Frontiers in oncology · 2023Article
- Sentinel Lymph Node in Non-Small Cell Lung Cancer: Assessment of Feasibility and Safety by Near-Infrared Fluorescence Imaging and Clinical Consequences.Journal of personalized medicine · 2022Article
- ABO blood classification and the risk of lung cancer: A meta-analysis and trial sequential analysis.Oncology letters · 2022Article
- Cell-by-Cell: Unlocking Lung Cancer Pathogenesis.Cancers · 2022Review
- Summary of best evidence for enhanced recovery after surgery for patients undergoing lung cancer operations.Asia-Pacific journal of oncology nursing · 2022Review
- Integration of Deep Learning Radiomics and Counts of Circulating Tumor Cells Improves Prediction of Outcomes of Early Stage NSCLC Patients Treated With Stereotactic Body Radiation Therapy.International journal of radiation oncology, biology, physics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
The past century has witnessed a transformative shift in lung cancer from a rare reportable disease to the leading cause of cancer death among men and women worldwide. This historic shift reflects the increase in tobacco consumption worldwide, spurring public health efforts over the past several decades directed at tobacco cessation and control. Although most lung cancers are still diagnosed at a late stage, there have been significant advances in screening high-risk smokers, diagnostic modalities, and chemopreventive approaches. Improvements in surgery and radiation are advancing our ability to manage early-stage disease, particularly among patients considered unfit for traditional open resection. Arguably, the most dramatic progress has occurred on the therapeutic side, with the development of targeted and immune-based therapy over the past decade. This article reviews the major shifts in the lung cancer landscape over the past 100 years. Although many ongoing clinical challenges remain, this review will also highlight emerging molecular and imaging-based approaches that represent opportunities to transform the prevention, early detection, and treatment of lung cancer in the years ahead.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.